Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 5, 2008
 
VANDA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
 
Delaware
(State or other jurisdiction of incorporation)
 
 
 
 
000-51863
 
03-0491827
(Commission File No.)
 
(IRS Employer Identification No.)
 
 
9605 Medical Center Drive
Suite 300
Rockville, Maryland 20850
(Address of principal executive offices and zip code)
 
Registrant’s telephone number, including area code: (240) 599-4500
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
 
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
 
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 
 

Item 7.01. Regulation FD disclosure

On June 5, 2008, Vanda Pharmaceuticals Inc. (“Vanda”) issued a joint press release with Laboratory Corporation of America® Holdings announcing that they had entered into an exclusive alliance to develop and commercialize a series of diagnostic tests for genetic markers identified by Vanda in the course of its clinical development of FanaptaTM (iloperidone). The full text of this press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in Item 7.01 of this Form 8-K and the press release furnished as Exhibit 99.1 to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


 
 
 

Item 9.01. Financial Statements and Exhibits.
 
(d)    Exhibits
 
Exhibit No.
 
Description
99.1
  
Press Release of Laboratory Corporation of America® Holdings and Vanda Pharmaceuticals Inc. dated June 5, 2008.
 
 

 

 
 
 

SIGNATURES
 
          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
VANDA PHARMACEUTICALS INC.
 
    
 
By:
/s/ STEVEN A. SHALLCROSS
 
 
Name:  Steven A. Shallcross
 
 
Title:  Senior Vice President, Chief Financial
Officer and Treasurer
 
 
Dated:  June 5, 2008